ArticleOncoimmunology2012

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Margaret A Lindorfer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.